These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 25840862)

  • 1. Epidemiological and statistical considerations for interpreting and communicating oncology clinical trials.
    Heller J
    Vet J; 2015 Aug; 205(2):233-7. PubMed ID: 25840862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Veterinary oncology clinical trials: design and implementation.
    Thamm DH; Vail DM
    Vet J; 2015 Aug; 205(2):226-32. PubMed ID: 25582798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Phase III trials in oncology].
    Imadalou K; Cvitkovic E
    Bull Cancer; 1999 Feb; 86(2):143-7. PubMed ID: 10066944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methodological aspects of biostatistics and epidemiology in a clinical trial].
    Suárez E; Pérez CM
    P R Health Sci J; 1999 Mar; 18(1):23-30. PubMed ID: 10343983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.
    Zhang S; Liang F; Li W; Hu X
    J Clin Oncol; 2015 May; 33(15):1697-702. PubMed ID: 25897150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application.
    Duff JM; Leather H; Walden EO; LaPlant KD; George TJ
    J Natl Cancer Inst; 2010 May; 102(10):702-5. PubMed ID: 20410466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When an interim analysis of randomized trial changes the practice in oncology: The lesson of adjuvant trastuzumab and the HERA trial.
    De Rossi C; Brunello A; Jirillo G; Jirillo A
    Immunopharmacol Immunotoxicol; 2009; 31(1):1-4. PubMed ID: 19238693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of evidence in the Journal of Veterinary Internal Medicine oncology manuscripts from 1999 to 2007.
    Sahora A; Khanna C
    J Vet Intern Med; 2010; 24(1):51-6. PubMed ID: 19780934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplicity in oncology randomised controlled trials: a threat to medical evidence?
    Prasad V; Booth CM
    Lancet Oncol; 2019 Dec; 20(12):1638-1640. PubMed ID: 31797779
    [No Abstract]   [Full Text] [Related]  

  • 11. Multi-arm clinical trials of new agents: some design considerations.
    Freidlin B; Korn EL; Gray R; Martin A
    Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Completeness of reporting in randomized controlled trials of 3 vaccines: a review of adherence to the CONSORT checklist.
    Scott P; Ott F; Egger M; Low N
    Pediatr Infect Dis J; 2012 Dec; 31(12):1286-94. PubMed ID: 22935870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conduct, Oversight, and Ethical Considerations of Clinical Trials in Companion Animals with Cancer: Report of a Workshop on Best Practice Recommendations.
    Page R; Baneux P; Vail D; Duda L; Olson P; Anestidou L; Dybdal N; Golab G; Shelton W; Salgaller M; Hardy C
    J Vet Intern Med; 2016; 30(2):527-35. PubMed ID: 26950524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised controlled trials in oncology closed early for benefit: trends in methodology, results, and interpretation.
    Booth CM; Ohorodnyk P; Zhu L; Tu D; Meyer RM
    Eur J Cancer; 2011 Apr; 47(6):854-63. PubMed ID: 21296570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival end point reporting in randomized cancer clinical trials: a review of major journals.
    Mathoulin-Pelissier S; Gourgou-Bourgade S; Bonnetain F; Kramar A
    J Clin Oncol; 2008 Aug; 26(22):3721-6. PubMed ID: 18669458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of clinical trials in veterinary oncology.
    Burton J; Khanna C
    Vet Clin North Am Small Anim Pract; 2014 Sep; 44(5):977-87. PubMed ID: 25174911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on the design of clinical trials for targeted therapies and immunotherapy in veterinary oncology.
    Marconato L; Buracco P; Aresu L
    Vet J; 2015 Aug; 205(2):238-43. PubMed ID: 25862396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.